NASDAQ · ENTX
Entera Bio Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ENTX: Nov 13, 2026
Entera Bio Ltd. Ordinary Shares is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.07.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · RTTNews · Zacks- Fintel · Oct 27, 11:20 AM EDTEntera Bio Ltd. Appoints Dr. Juan Camilo Arjona Ferreira to Board of DirectorsOn October 27, 2026, the Board of Directors (the “Board”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director of the Company, effective December
- Fintel · Sep 25, 10:58 AM EDTGuggenheim Initiates Coverage of Entera Bio with BuyFintel reports that on September 25, 2026, Guggenheim initiated coverage of Entera Bio (NASDAQCM:ENTX) (DB:5DT) with a Buy recommendation.This initiation follows other recent analyst actions. On September 22, 2026, Cantor Fitzgerald initiated coverage of the company with an Overw
- Fintel · Sep 18, 8:12 PM EDTLeerink Partners Initiates Coverage of Entera Bio with Outperform RatingFintel reports that on September 18, 2026, Leerink Partners initiated coverage of Entera Bio (NASDAQCM:ENTX) (DB:5DT) with a Outperform recommendation. This initiation represents the sole rating action recorded for the company on September 18, 2026, by Leerink Partners.Entera Bio
- MarketBeat · Aug 13, 2:04 PM EDTEntera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA AgreementEntera Bio (NASDAQ:ENTX) plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a disc
- RTTNews · Aug 10, 6:05 AM EDTEntera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28(RTTNews) – Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further, the company plans to initiate Phase 3 stu
- RTTNews · Jul 27, 11:29 PM EDTTop Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired(RTTNews) – Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debu
- RTTNews · Jul 27, 11:32 AM EDTEntera Raises $275 Mln In Private Placement To Advance EB613 Into Phase 3; Stock Surges 73%(RTTNews) – Entera Bio Ltd. (ENTX), a clinical-stage biotechnology company developing oral peptide therapies, Monday announced a securities purchase agreement for an oversubscribed private placement expected to generate approximately $275 million in gross proceeds.
- Zacks · Jul 21, 10:39 AM EDTEntera Bio Stock Rallies 35% in a Month: Here's What You Should KnowENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
- RTTNews · Jul 16, 10:52 PM EDTTop Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch(RTTNews) – Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to be acquired by Eli Lilly; and Abbott, afte
- Zacks · Jun 29, 8:32 AM EDTTake the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in FocusDELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.
- RTTNews · Jun 22, 10:45 AM EDTEntera Bio Gains FDA Alignment For 12-Month Phase 3 Study Of EB613, First Oral Anabolic Tablet(RTTNews) – Entera Bio Ltd. (ENTX) received positive FDA feedback on its planned 12-month registrational Phase 3 study of EB613, positioning the program for a potential New Drug Application based on one pivotal trial.
- Zacks · Apr 29, 12:00 PM EDTEntera Bio (ENTX) Upgraded to Buy: Here's What You Should KnowEntera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Entera Bio Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.